BCL2L10 and cancer: Ubiquitin-dependent proteasomal degradation has been foundto affect Bcl2L10 function as regulator of apoptosis, while increased expression ofBcl2L10 by gene amplification has been linked to acquired drugresistance in cancer cells [23, 24].